What is the optimal management for a patient with anxiety on duloxetine 60 mg daily and as‑needed hydroxyzine who continues to exhibit floor‑throwing behavior, with hydroxyzine ineffective and increasing fall risk?

Management of Ineffective Hydroxyzine in an Anxious Patient on Duloxetine

Stop the hydroxyzine immediately—it is ineffective for this patient, increases fall risk even in non-ambulatory patients (through sedation and cognitive impairment), and the most recent high-quality evidence shows benzodiazepines and antihistamines like hydroxyzine pose excessive risks in managing agitation, particularly when behavioral interventions remain unexplored 1.

Immediate Action Plan for Tomorrow's Visit

1. Discontinue Hydroxyzine

• Hydroxyzine has failed the 14-day trial with no therapeutic benefit
• Even though the patient scoots rather than walks, hydroxyzine increases fall risk through sedation, cognitive impairment, and coordination problems 1
• Research shows hydroxyzine's anxiolytic effects are modest at best, with drowsiness as the primary side effect 2, 3
• The combination of duloxetine with hydroxyzine provides no additional benefit over monotherapy 4

2. Conduct Behavioral Assessment

Critical questions to ask the patient:

• What triggers the floor-throwing behavior? (specific people, times, requests, activities)
• What happens immediately before each episode?
• What does he gain from this behavior? (staff attention, avoidance of activities, control)
• Does he feel anxious before doing it, or is it a learned response to get needs met?
• What calms him down effectively when he's genuinely anxious?

Distinguish true anxiety from behavioral manipulation:

• True anxiety: physiologic symptoms (tachycardia, sweating, tremor), pervasive worry, responds to reassurance
• Behavioral: occurs selectively with certain staff/situations, stops when desired outcome achieved, escalates with attention

3. Optimize Duloxetine Dosing

The patient is on 60 mg daily, which is the standard target dose 5. However:

• If true anxiety persists despite behavioral interventions, duloxetine can be increased to 90-120 mg daily 5
• Dose escalation is safe and well-tolerated, with most side effects occurring at initial 60 mg dosing, not with subsequent increases 6
• Caution: Duloxetine can paradoxically cause or worsen anxiety and agitation in some patients 7
• Monitor for 1-2 weeks after any dose increase before further adjustments

4. Address Staff Dynamics

The daily complaints suggest:

• Staff may be inadvertently reinforcing the behavior through attention
• Implement a consistent behavioral plan across all staff:
  • Minimal attention during floor-throwing episodes
  • Ensure safety without excessive engagement
  • Redirect calmly without negotiation
  • Provide positive attention for appropriate behavior
  • Document triggers and patterns objectively

5. Alternative Pharmacologic Options (If Needed)

Only after behavioral interventions fail and true anxiety is confirmed:

First-line alternatives to hydroxyzine:

• Quetiapine 25-50 mg PRN: The 2025 geriatric guidelines show quetiapine has the lowest adverse event rate among agents for agitation (OR 0.27 vs haloperidol) 1
• Lorazepam 0.5-1 mg PRN: If rapid anxiolysis needed, though benzodiazepines carry risks 8

Avoid:

• Midazolam (excessive adverse events, OR 5.25 vs haloperidol) 1
• Additional antihistamines
• Scheduled benzodiazepines (dependence risk)

6. Non-Pharmacologic Interventions

Implement immediately:

• Structured daily routine with predictable activities
• Identify and address unmet needs (pain, boredom, loneliness)
• Sensory interventions (music, tactile activities)
• Regular check-ins before behaviors escalate
• Environmental modifications to reduce triggers

Common Pitfalls to Avoid

1. Continuing ineffective medications: Hydroxyzine has failed—don't extend the trial
2. Assuming all agitation is anxiety: This appears behavioral; treating with more anxiolytics will fail
3. Responding to staff pressure with inappropriate prescribing: Staff need behavioral management training, not more PRN medications
4. Ignoring duloxetine as a potential contributor: SNRIs can cause paradoxical anxiety 7
5. Polypharmacy without behavioral assessment: Adding medications without understanding the behavior's function

Documentation Strategy

Document clearly:

• Hydroxyzine trial failed (no benefit, continued behaviors)
• Behavioral assessment findings and triggers identified
• Behavioral plan implemented with staff education
• Rationale for any medication changes
• Staff expectations reset regarding realistic outcomes

The floor-throwing behavior will likely persist until its function is understood and alternative behaviors are reinforced—no medication will eliminate a learned behavioral pattern that successfully meets the patient's needs.